Miransertib (ARQ 092) HCl,1313883-00-9

Miransertib (ARQ 092) HCl,1313

883-00-9
收藏
  • ¥1268 - 4355
  • 爱必信(absin)
  • 上海
  • abs811997
  • 2025年07月12日
    avatar
  • 企业认证

    • 详细信息
    • 技术资料
    • 保存条件

      Store at -20℃ for one year(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution.

    • 库存

      99

    • 供应商

      爱必信(上海)生物科技有限公司

    • CAS号

      1313883-00-9

    • 规格

      25mg/5mg

    规格:25mg产品价格:¥4355.0
    规格:5mg产品价格:¥1268.0

    公告提醒:爱必信所有产品和服务仅用于科学研究不用于临床应用及其他用途提供产品和服务也不为任何个人提供产品和服务)!

     

    抑制剂描述:

    产品名称:Miransertib (ARQ 092) HCl

    产品别名:见爱必信官网

    英文别名:Miransertib (ARQ 092) HCl

    靶点:Akt

    CAS:1313883-00-9

    纯度:>98%

    外观:见爱必信官网

    保存方法:Store at -20℃ for one year(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution.

    描述:

    ARQ 092 is a novel, orally bioavailable and selective AKT pathway inhibitor exhibiting a manageable safety profile among patients with advanced solid tumors.

    溶解性:DMSO :86 mg/mL (183.38 mM)

    体外研究:

    ARQ 092 blocks membrane translocation of inactive AKT and even dephosphorylates the membrane-associated active form, thereby perturbing AKT activity. Treatment with 50-500 nM ARQ 092 significantly blocks αMβ2 integrin function in neutrophils and reduces P-selectin exposure and glycoprotein Ib/IX/V-mediated agglutination in platelets. In a large panel of diverse cancer cell lines, ARQ 092 inhibits proliferation across multiple tumor types but are most potent in leukemia, breast, endometrial, and colorectal cancer cell lines. Moreover, inhibition by ARQ 092 is more prevalent in cancer cell lines containing PIK3CA/PIK3R1 mutations compared to those with wt-PIK3CA/PIK3R1 or PTEN mutations. ARQ 092 targets the PI3K/AKT pathway and AKT specifically and reduces phosphorylation of GSK3α and GSK3β in mutation-positive cells.

    体内研究:Short-term oral administration of ARQ 092 or hydroxyurea, a main therapy for sickle cell disease, diminishes heterotypic cell-cell interactions in venules of sickle cell disease mice challenged with TNF-α. ARQ 092 is well tolerated at a continuous daily dose of 60 mg or a dose of 600 mg when administered once a week, for several months. ARQ 092 is likely to inhibit the activity of all AKT isoforms in intravascular cells and thereby attenuates the process of thrombosis and inflammation in SCD patients. ARQ 092 is highly active in a subset of endometrial tumors that harbor PI3K pathway gene mutations.

    产品信息订购:

      产品货号   产品名称   规格 价格 大包装及货期
      abs811997   Miransertib (ARQ 092) HCl   5mg   1268.00   立即咨询
      abs811997   Miransertib (ARQ 092) HCl   25mg   4355.00   立即咨询

    产品更多信息请进入爱必信(absin)商城查看》》》



    absin,您身边的科研百宝箱
    专业提供试剂、耗材、仪器,在线订购,7*24h全国发货,方便快捷!

    风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。

    图标技术资料

    暂无技术资料 索取技术资料

    同类产品报价

    产品名称
    产品价格
    公司名称
    报价日期
    ¥1085
    MedChemExpress LLC
    2025年12月05日询价
    ¥536
    TargetMol中国
    2025年07月11日询价
    ¥12368
    武汉博欧特生物科技有限公司
    2025年07月09日询价
    ¥3904
    深圳欣博盛生物科技有限公司
    2025年07月15日询价
    询价
    艾美捷科技有限公司
    2025年07月15日询价
    Miransertib (ARQ 092) HCl,1313883-00-9
    ¥1268 - 4355